Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Clinical studies show 20 to 30 percent improvement in skin firmness after 12 weeks, with significant gains occurring in this middle period
Following subcutaneous administration in clinical models: Both components demonstrate prolonged absorption with peak plasma concentrations occurring 24-72 hours post-injection GLP3 exhibits approximately 6-day half-life enabling once-weekly dosing Cagrilintide demonstrates 120-165 hour half-life (5-7 days) suitable for weekly administration Lipid conjugation of both peptides enables albumin binding and extended systemic circulation Distribution patterns show systemic exposure with concentration in metabolically active tissues The fatty diacid modifications on both peptides (C20 for GLP3 , eicosanedioic acid for cagrilintide) serve as albumin-binding moieties that dramatically extend plasma residence time compared to native peptides
It carries the molecular formula C194H312N54O59S2 with a molecular weight of 4409 g/mol and the CAS number 1415456-99-3
Currently under clinical investigation and not yet FDA-approved, Cagrilintide is being studied for its role in weight management, appetite suppression, and metabolic support, both as a standalone therapy and in combination with Semaglutide
It is designed to signal fat breakdown without the blood sugar or growth effects of full HGH
Potential Hair & Scalp Benefits 1
US$ 25.07
US$ 20.90
US$ 28.39
US$ 23.58
US$ 29.52
